ArticleBritish journal of haematology2025

A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned.

Najla El Jurdi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.